Streamlining Specialty Drug Prior Auth with Klivira
Klivira revolutionizes specialty drug prior auth by automating complex benefit determination, multi-channel submission, and critical documentation for high-cost therapies.
Specialty drugs, encompassing biologics, biosimilars, and complex injectables, represent a significant and growing segment of healthcare spend. Navigating their prior authorization (PA) requirements is notoriously complex, often involving distinct workflows for medical versus pharmacy benefits, diverse submission channels, and stringent clinical documentation needs. This complexity directly impacts time-to-therapy, patient access, and revenue cycle efficiency.
The Challenge of Specialty Drug Prior Authorization
Traditional specialty drug PA workflows are highly manual and prone to errors, leading to delays and increased administrative burden. Staff must determine the correct benefit side (medical vs. pharmacy), choose the appropriate submission channel, and meticulously gather extensive clinical documentation, often for each drug and payer combination. This fragmented process creates significant operational bottlenecks.
Common Failure Modes in Manual Specialty Drug PA
- **Benefit-side misclassification:** Incorrectly routing a drug under the medical vs. pharmacy benefit, leading to immediate denials.
- **Site-of-care policy violations:** Submitting for an infusion site that conflicts with payer policies, requiring rework.
- **Step-therapy documentation gaps:** Insufficient evidence of prior-line therapy, a frequent requirement for biologic approvals.
- **Specialty pharmacy fulfillment delays:** Post-approval handoff to specialty pharmacies adding days to time-to-medication.
- **Copay assistance navigation complexity:** Challenges in identifying and applying manufacturer copay assistance, especially with Medicare patient exclusions.
Klivira's Automated Specialty Drug PA Workflow
Klivira's platform provides an end-to-end solution for specialty drug prior authorization, spanning both medical and pharmacy benefits. Our automation engine precisely identifies the correct benefit side per drug, per payer, and per patient context, eliminating common misclassification errors. This intelligent routing ensures submissions reach the right channel the first time, accelerating approvals.
Key Automation Capabilities for Specialty Drugs
- **Automated Benefit-Side Determination:** Klivira's policy engine accurately identifies whether a specialty drug falls under the medical or pharmacy benefit, based on drug, payer, and patient context.
- **Multi-Channel Submission:** Pharmacy-benefit specialty drugs route through ePA partners like CoverMyMeds (src: covermymeds) and Surescripts (src: surescripts) using the NCPDP SCRIPT ePA standard (src: ncpdp-script). Medical-benefit drugs utilize X12 278 EDI and Da Vinci PAS (src: davinci-pas-ig) where available, or payer portals.
- **Step-Therapy & Documentation Automation:** Klivira leverages FHIR MedicationRequest and Observation resources to capture and document prior-line therapy and treatment response data, fulfilling critical step-therapy requirements.
- **Site-of-Care Policy Alignment:** Our system incorporates payer site-of-care policies, surfacing requirements for alternative infusion sites before submission to avoid denials.
- **Specialty Pharmacy Fulfillment Coordination:** Klivira coordinates the post-approval handoff to specialty pharmacies, streamlining the path from PA approval to patient medication delivery.
- **Copay Assistance Identification:** The workflow identifies manufacturer copay-assistance program availability and flags Medicare patient exclusions for compliance considerations.
Leveraging Industry Standards for Specialty Drug PA
Klivira's platform is built on robust industry standards to ensure interoperability and efficiency across the PA ecosystem. We utilize NCPDP SCRIPT (src: ncpdp-script) for pharmacy ePA, FHIR MedicationRequest for detailed clinical data exchange, Da Vinci PAS (src: davinci-pas-ig) for medical benefit prior authorization services, and X12 278 for traditional EDI submissions. This standards-based approach ensures seamless integration with EMRs and payer systems, critical for the complex landscape of specialty drug PA.
Addressing the CAQH Index Insights for Specialty Drugs
The CAQH Index (src: caqh-index) consistently highlights the operational and financial impact of manual prior authorization. Specialty drug PA uniquely spans both pharmacy and medical benefit transactions, areas where electronic adoption rates vary. Klivira's comprehensive approach bridges this gap, bringing automation to both sides of the benefit determination for specialty drugs, enhancing efficiency where it's most needed.
Frequently asked questions
How does Klivira handle the distinction between medical and pharmacy benefits for specialty drugs?
Klivira's policy engine automatically determines the correct benefit side (medical or pharmacy) for each specialty drug based on the specific payer, patient context, and drug characteristics. This intelligence ensures the PA request is routed to the appropriate channel from the outset, preventing misclassification errors and rework.
What standards does Klivira utilize for specialty drug prior authorization submissions?
Klivira supports key industry standards including NCPDP SCRIPT (src: ncpdp-script) for pharmacy ePA, FHIR MedicationRequest for clinical data, Da Vinci PAS (src: davinci-pas-ig) for medical benefit PA, and X12 278 for EDI. This multi-standard approach ensures comprehensive connectivity across diverse payer and PBM systems.
Can Klivira integrate with our existing EMR to pull patient data for specialty drug PAs?
Yes, Klivira is designed for seamless integration with EMRs, leveraging SMART on FHIR capabilities. This allows for automated extraction of critical patient data, including medication history and treatment response from FHIR MedicationRequest and Observation resources, directly into the PA submission, reducing manual data entry.
Does Klivira manage the specialty pharmacy fulfillment process after PA approval?
Klivira coordinates the post-approval handoff to specialty pharmacies for pharmacy-benefit drugs. While we don't directly manage the logistics of drug delivery, our system streamlines the information transfer, helping to reduce delays in the fulfillment workflow once the PA is approved.
How does Klivira assist with site-of-care requirements for medical benefit specialty drugs?
Klivira incorporates payer-specific site-of-care policies into the PA workflow. Before submission, our system can flag instances where the proposed site of care may not align with payer requirements, allowing your team to address potential issues proactively and avoid denials related to site-of-care policies.
Related coverage
Ready to ship this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo